Recent Updates
Recently added Catalysts
GKOS Positive Sentiment

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Wednesday, October 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Glaukos Corporation has announced positive topline results from a Phase 3 extension study of Epioxa®, its innovative therapy for keratoconus. The study highlights the durability and visual outcomes of the treatment, indicating its potential effectiveness and safety for patients. This marks a significant advancement in the management of corneal disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive topline results from a long-term Phase 3 study.
  • Epioxa® demonstrates durable clinical outcomes.
  • The therapy shows promising visual outcomes and safety.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
8.7%
average across 4 past catalysts
Lead asset
Test Article A
Phase 3 · Progressive Keratoconus

Full Press Release Details

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh

Frequently Asked Questions

What is Epioxa® used for?

Epioxa® is used for the treatment of keratoconus.

What were the results of the Phase 3 study?

The Phase 3 study showed positive topline results, indicating durable clinical outcomes.

How does Epioxa® impact visual outcomes?

Epioxa® demonstrated promising visual outcomes in the long-term study.

What is the focus of Glaukos Corporation?

Glaukos focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases.

ShareAdd on Google
Tags: GKOS Glaukos Epioxa keratoconus Phase 3 clinical outcomes
Last updated: Oct 7, 2026

Biotech snapshot

Cash runway
$286M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Test Article APhase 3
Progressive Keratoconus →

Catalyst track record

+66%
best trade around GKOS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GKOS.

See every catalyst's timing & PoA →